Consultation record
Submissions accepted — page 23
The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Submissions
735 documents · page 23 of 25
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-SLEEP-APNOEA/004 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Lorcan Whitmarsh-Obi | Doses differing several-fold are pooled without examining dose-response |
| DRAFT-SLEEP-APNOEA/005 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Yaa Kettlewell | Studies using different outcome definitions are pooled into one estimate |
| DRAFT-SLEEP-APNOEA/008 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Ludmila Tollemache | An indirect comparison is presented without an assessment of transitivity |
| DRAFT-SLEEP-APNOEA/009 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Liesbeth Zaleski-Mbeki | The comparator was given at a dose below the one in general use |
| DRAFT-SLEEP-APNOEA/010 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Yusuf Whitmarsh-Obi | One trial appears to be included twice under two publications |
| DRAFT-SLEEP-APNOEA/011 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Ivo Quintanilha | Risk-of-bias judgements are reported as an overall rating without the domains |
| DRAFT-SLEEP-APNOEA/014 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Ivo Mountstephen | The search strategy as published cannot be re-run |
| DRAFT-SLEEP-APNOEA/016 | Draft synthesis: Weight-reducing agents for obstructive sleep apnoea | Dr Jozef Brandvold-Achterberg | Registered trials that never reported are not counted anywhere in the review |
| DRAFT-COA-COMPLETE/001 | Draft synthesis: Completeness of certificates of analysis in the… | Dr Ndidi Ravensworth-Ilunga | Risk-of-bias judgements are reported as an overall rating without the domains |
| DRAFT-COA-COMPLETE/006 | Draft synthesis: Completeness of certificates of analysis in the… | Dr Xenia Nyquist-Obiora | Time between manufacture and analysis is not accounted for |
| DRAFT-COA-COMPLETE/008 | Draft synthesis: Completeness of certificates of analysis in the… | Dr Evander Ashworth-Danquah | The same concept is given three different names in one document |
| DRAFT-COUNTERION-C/004 | Draft synthesis: Counter-ion content and its effect on delivered… | Dr Ivo Quintanilha | Risk-of-bias judgements are reported as an overall rating without the domains |
| DRAFT-COUNTERION-C/006 | Draft synthesis: Counter-ion content and its effect on delivered… | Thaddeus Isaksen-Balogun | Studies using different outcome definitions are pooled into one estimate |
| DRAFT-COUNTERION-C/011 | Draft synthesis: Counter-ion content and its effect on delivered… | Dr Yaa Kettlewell | A funnel plot is presented for a set too small to interpret it |
| DRAFT-COUNTERION-C/012 | Draft synthesis: Counter-ion content and its effect on delivered… | Quentin Whitmarsh-Obi | The search strategy as published cannot be re-run |
| DRAFT-COUNTERION-C/013 | Draft synthesis: Counter-ion content and its effect on delivered… | Dr Ndidi Ravensworth-Ilunga | The sampling frame of each contributing survey is not reported |
| DRAFT-COUNTERION-C/014 | Draft synthesis: Counter-ion content and its effect on delivered… | Dr Jozef Brandvold-Achterberg | The conclusion is stated more strongly than the certainty rating supports |
| DRAFT-COUNTERION-C/016 | Draft synthesis: Counter-ion content and its effect on delivered… | Dr Quentin Zimmerthal | Results obtained by different methods are pooled without recording the method |
| DRAFT-BPC-157-HUMA/001 | Draft synthesis: Human evidence for BPC-157 | Dr Oisín Rautavaara | A funnel plot is presented for a set too small to interpret it |
| DRAFT-GH-SECRETAGO/002 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Dr Oisín Rautavaara | Intention-to-treat and efficacy-estimand results are combined without distinction |
| DRAFT-GH-SECRETAGO/003 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Dr Lorcan Whitmarsh-Obi | The comparator was given at a dose below the one in general use |
| DRAFT-GH-SECRETAGO/004 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Thaddeus Isaksen-Balogun | A funnel plot is presented for a set too small to interpret it |
| DRAFT-GH-SECRETAGO/005 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Stellan Cholmondeley-Ade | The search date is not on the face of the document |
| DRAFT-GH-SECRETAGO/006 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Dr Yusuf Whitmarsh-Obi | Results at materially different follow-up durations are pooled |
| DRAFT-GH-SECRETAGO/007 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Anselm Mountstephen | The review does not say when it will be updated or what would trigger an update |
| DRAFT-GH-SECRETAGO/008 | Draft synthesis: Clinical evidence for growth-hormone secretagogues… | Dr Kolawole Isaksen-Balogun | Overlapping primary studies across included reviews are counted more than once |
| DRAFT-RUSSIAN-REGI/001 | Draft synthesis: Nationally registered neuropeptides and the… | Bertrand Ollerenshaw industry | Two factual descriptions of the sponsor's programme are inaccurate |
| DRAFT-RUSSIAN-REGI/005 | Draft synthesis: Nationally registered neuropeptides and the… | Dr Lorcan Trelawney | Efficacy outcomes are rated for certainty and harms are not |
| DRAFT-RUSSIAN-REGI/006 | Draft synthesis: Nationally registered neuropeptides and the… | Dr Henrike Jastrzębska | The comparator was given at a dose below the one in general use |
| DRAFT-RUSSIAN-REGI/009 | Draft synthesis: Nationally registered neuropeptides and the… | Dr Oisín Rautavaara | Overlapping primary studies across included reviews are counted more than once |
page 23 of 25